Assad Daniele Xavier, Mascarenhas Elisa Cançado Porto, Normando Ana Gabriela Costa, Chardin Hélène, Barra Gustavo Barcelos, Pratesi Riccardo, Nóbrega Yanna Karla de Medeiros, Acevedo Ana Carolina, Guerra Eliete Neves Silva
Laboratory of Oral Histopathology, Health Sciences Faculty, University of Brasília Campus Universitário Darcy Ribeiro, Brasília, DF 70910-900, Brazil.
Medical Oncology Department, Hospital Sírio-Libanês, Brasília, DF 70200-730, Brazil.
Mol Clin Oncol. 2020 Aug;13(2):155-161. doi: 10.3892/mco.2020.2062. Epub 2020 Jun 4.
The early detection of breast cancer enables the use of less aggressive treatment and increases patient survival. The transmembrane glycoprotein mucin 1, which is also known as cancer antigen 15-3 (CA15-3), is aberrantly glycosylated and overexpressed in a variety of epithelial cancers, and serves a crucial role in the progression of the disease. CA15-3 is currently used as a marker of breast cancer. In the present study, CA15-3 concentrations in saliva and blood of patients with breast cancer were evaluated to test new assays to detect salivary CA15-3 in addition to ELISA and its diagnostic value. To the best of our knowledge, there are no previous reports of the use of chemiluminescence assay (CLIA) and electrochemiluminescence assay (ECLIA) in saliva. Saliva and blood were collected on the same day from patients with breast cancer (n=26) and healthy controls (n=28). For each subject, the level of serum CA15-3 was measured using ECLIA, and the level of salivary CA15-3 was measured using ECLIA, CLIA and enzyme-linked immunosorbent assay (ELISA). ELISA and CLIA were able to detect CA15-3 in saliva; however, ECLIA could not detect salivary CA15-3. There was no significant difference between the mean serum and salivary CA15-3 levels in patients with breast cancer or healthy controls. The levels of CA15-3 were highest for luminal breast cancer subtypes and stage IV cases. A moderate correlation was observed between salivary and serum CA15-3 levels as measured by ELISA in breast cancer patients (r=0.56; P=0.0047). The results demonstrated that ECLIA was not a good method to detect salivary CA15-3, although it is the gold standard for detecting serum CA15-3. The presence of CA15-3 in saliva was confirmed, and this will be useful in future research. Further investigations are necessary to confirm the ability to detect salivary CA15-3 and its correlation with serum CA15-3.
乳腺癌的早期检测能够采用侵袭性较小的治疗方法，并提高患者生存率。跨膜糖蛋白黏蛋白1，也被称为癌抗原15-3（CA15-3），在多种上皮癌中发生异常糖基化并过度表达，在疾病进展中起关键作用。CA15-3目前用作乳腺癌的标志物。在本研究中，评估了乳腺癌患者唾液和血液中的CA15-3浓度，以测试除酶联免疫吸附测定（ELISA）及其诊断价值外检测唾液CA15-3的新方法。据我们所知，以前没有关于在唾液中使用化学发光测定法（CLIA）和电化学发光测定法（ECLIA）的报道。同一天从乳腺癌患者（n = 26）和健康对照者（n = 28）中采集唾液和血液。对于每个受试者，使用ECLIA测量血清CA15-3水平，使用ECLIA、CLIA和酶联免疫吸附测定（ELISA）测量唾液CA15-3水平。ELISA和CLIA能够检测唾液中的CA15-3；然而，ECLIA无法检测唾液中的CA15-3。乳腺癌患者或健康对照者的血清和唾液CA15-3平均水平之间没有显著差异。管腔型乳腺癌亚型和IV期病例的CA15-3水平最高。通过ELISA测量，乳腺癌患者唾液和血清CA15-3水平之间观察到中度相关性（r = 0.56；P = 0.0047）。结果表明，尽管ECLIA是检测血清CA15-3的金标准，但它不是检测唾液CA15-3的好方法。唾液中CA15-3的存在得到证实，这将对未来研究有用。需要进一步研究以确认检测唾液CA15-3的能力及其与血清CA15-3的相关性。
